Chemotherapy and quality of life in NSCLC PS 2 patients

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106–30
   PubMed Web of Science ®Google Scholar
• Kelly K. Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status. Semin Oncol 2004; 31: 3–7
   PubMed Web of Science ®Google Scholar
• Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995; 13: 1221–30
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001; 92: 2639–47
   PubMed Web of Science ®Google Scholar
• Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65: 25–32
   PubMed Web of Science ®Google Scholar
• Fallowfield LJ, Harper P. Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer 2005; 48: 365–77
   PubMed Web of Science ®Google Scholar
• Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1996;14:671–9.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Ardizzoni A, Le CT, Manegold C, Perrone F, Thatcher N, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: Results of an European Experts Panel. Ann Oncol 2004; 15: 419–26
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Clinical Guideline 24, Lung cancer: the diagnosis and treatment of lung cancer. 2005, (Report).
   Google Scholar
• Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai SH. Health-related quality of life in non-small-cell lung cancer: Methodologic issues in randomized controlled trials. J Clin Oncol 2003; 21: 2982–92
   PubMed Web of Science ®Google Scholar
• Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Jr, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004; 22: 330–53
   PubMed Web of Science ®Google Scholar
• Billingham LJ, Cullen MH. The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann Oncol 2001; 12: 1671–5
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92–8
   PubMed Web of Science ®Google Scholar
• Soria JC, Brisgand D, Le Chevalier T. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?. Ann Oncol 2001; 12: 1667–70
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The cancer and leukemia group B (study 9730). J Clin Oncol 2005; 23: 190–6
   PubMed Web of Science ®Google Scholar
• Helbekkmo N, Aasebo U, Sundstrom SH, von Plessen C, Brunsvig PF, Bremnes RM. Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy. Lung Cancer 2008; 62: 253–60
   PubMed Web of Science ®Google Scholar
• Helbekkmo N, Sundstrom SH, Aasebo U, Brunsvig PF, von Plessen C, Hjelde HH, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007; 97: 283–9
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–55
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76
   PubMed Web of Science ®Google Scholar
• Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994; 30A: 635–42
   PubMed Web of Science ®Google Scholar
• Fayers, PM, Aaronson, NK, Bjordal, K, Groenvold, M, Curran, D, Bottomley, A. EORTC QLQ-30. Scoring Manual 3rd ed. 2001.
   Google Scholar
• Fairclough DL. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med 1997; 16: 1197–209
   PubMed Web of Science ®Google Scholar
• Fayers, PM, Machin, D. Quality of Life. Assessment, analysis and interpretetation. 1st ed. Chichester: John Wiley and Sons Ltd.; 2000.
   Google Scholar
• Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J. Analysis and interpretation of health-related quality-of-life data from clinical trials: Basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005; 41: 280–7
   PubMed Web of Science ®Google Scholar
• Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 1999; 17: 3188–94
   PubMed Web of Science ®Google Scholar
• Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008; 26: 863–9
   PubMed Web of Science ®Google Scholar
• Bernhard J, Cella DF, Coates AS, Fallowfield L, Ganz PA, Moinpour CM, et al. Missing quality of life data in cancer clinical trials: Serious problems and challenges. Stat Med 1998; 17: 517–32
   PubMed Web of Science ®Google Scholar
• Herndon JE, Fleishman S, Kosty MP, Green MR. A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. Control Clin Trials 1997; 18: 286–300
   PubMedGoogle Scholar
• Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007; 357: 2189–94
   PubMed Web of Science ®Google Scholar
• Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999; 17: 1654–63
   PubMed Web of Science ®Google Scholar
• Tishelman C, Degner LF, Rudman A, Bertilsson K, Bond R, Broberger E, et al. Symptoms in patients with lung carcinoma: Distinguishing distress from intensity. Cancer 2005; 104: 2013–21
   PubMed Web of Science ®Google Scholar